Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse
Open Access
- 1 March 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 8 (1), E196-E203
- https://doi.org/10.1208/aapsj080124
Abstract
The discovery and preclinical development of selective dopamine reuptake inhibitors as potential pharmacotherapies for treating cocaine addiction are presented. The studies are based on the hypothesis that a dopamine reuptake inhibitor is expected to partially substitute for cocaine, thus decreasing cocaine self-administration and minimizing the craving for cocaine. This type of indirect agonist therapy has been highly effective for treating smoking addiction (nicotine replacement therapy) and heroin addiction (methadone). To be an effective pharmacotherapy for cocaine addiction, the potential drug must be safe, long-acting, and have minimal abuse potential. We have developed several 3-phenyltropane analogs that are potent dopamine uptake inhibitors, and some are selective for the dopamine transporter relative to the serotonin and norepinephrine transporters. In animal studies, these compounds substitute for cocaine, reduce the intake of cocaine in rats and rhesus monkeys trained to self-administer cocaine, and have demonstrated a slow onset and long duration of action and lack of sensitization. The 3-phenyltropane analogs were also tested in a rhesus monkey self-administration model to define their abuse potential relative to cocaine. Based on these studies, 3beta-(4-chlorophenyl)-2beta-[3-(4'-methylphenyl)isoxazol-5-yl]tropane (RTI-336) has been selected for preclinical development.Keywords
This publication has 24 references indexed in Scilit:
- Why does the rapid delivery of drugs to the brain promote addiction?Trends in Pharmacological Sciences, 2005
- Monoamine Transporter Binding, Locomotor Activity, and Drug Discrimination Properties of 3-(4-Substituted-phenyl)tropane-2-carboxylic Acid Methyl Ester IsomersJournal of Medicinal Chemistry, 2004
- Dopamine in drug abuse and addiction: results from imaging studies and treatment implicationsMolecular Psychiatry, 2004
- Effects of Dopamine Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys: Relationship to Transporter Occupancy Determined by Positron Emission Tomography NeuroimagingThe Journal of pharmacology and experimental therapeutics, 2004
- Synthesis, Monoamine Transporter Binding Properties, and Behavioral Pharmacology of a Series of 3β-(Substituted phenyl)-2β-(3‘-substituted isoxazol-5-yl)tropanesJournal of Medicinal Chemistry, 2003
- The Reinforcing Efficacy of the Dopamine Reuptake Inhibitor 2β-Propanoyl-3β-(4-tolyl)-tropane (PTT) as Measured by a Progressive-Ratio Schedule and a Choice Procedure in Rhesus MonkeysThe Journal of pharmacology and experimental therapeutics, 2002
- Reinforcing Strength of a Novel Dopamine Transporter Ligand: Pharmacodynamic and Pharmacokinetic MechanismsThe Journal of pharmacology and experimental therapeutics, 2002
- Pharmacotherapies for Treatment of Cocaine Abuse: Preclinical AspectsJournal of Medicinal Chemistry, 1999
- Potent substituted-3β-phenyltropane analogs of cocaine have cocaine-like discriminative stimulus effectsDrug and Alcohol Dependence, 1991
- The dopamine hypothesis of the reinforcing properties of cocaineTrends in Neurosciences, 1991